{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:42:21Z","timestamp":1791805341193,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to characterize severe immune-related adverse events (irAEs) seen among hospitalized patients and to examine risk factors for irAE admissions and clinically relevant outcomes, including length of stay, immune checkpoint inhibitor (ICI) discontinuation, readmission, and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who received ICI therapy (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, or any ICI combination) at Massachusetts General Hospital (MGH) and were hospitalized at MGH following ICI initiation between January 1, 2011, and October 24, 2018, were identified using pharmacy and hospital admission databases. Medical records of all irAE admissions were reviewed, and specialist review with defined criteria was performed. Demographic data, relevant clinical history (malignancy type and most recent ICI regimen), and key admission characteristics, including dates of admission and discharge, immunosuppressive management, ICI discontinuation, readmission, and death, were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 450 admissions were classified as irAE admissions and represent the study's cohort. Alongside the increasing use of ICIs at our institution, the number of patients admitted to MGH for irAEs has gradually increased every year from 9 in 2011 to 92 in 2018. The hospitalization rate per ICI recipient has declined over that same time period (25.0% in 2011 to 8.5% in 2018). The most common toxicities leading to hospitalization in our cohort were gastrointestinal (30.7%; n =\u2009138), pulmonary (15.8%; n =\u200971), hepatic (14.2%; n =\u200964), endocrine (12.2%; n = 55), neurologic (8.4%; n =\u200938), cardiac (6.7%; n =\u200930), and dermatologic (4.4%; n =\u200920). Multivariable logistic regression revealed statistically significant increases in irAE admission risk for CTLA-4 monotherapy recipients (odds ratio [OR], 2.02; p &amp;lt; .001) and CTLA-4 plus PD-1 combination therapy recipients (OR, 1.88; p &amp;lt; .001), relative to PD-1\/PD-L1 monotherapy recipients, and patients with multiple toxicity had a 5-fold increase in inpatient mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study illustrates that cancer centers must be prepared to manage a wide variety of irAE types and that CTLA-4 and combination ICI regimens are more likely to cause irAE admissions, and earlier. In addition, admissions for patients with multi-organ involvement is common and those patients are at highest risk of inpatient mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>\u200aThe number of patients admitted to Massachusetts General Hospital for immune-related adverse events (irAEs) has gradually increased every year and the most common admissions are for gastrointestinal (30.7%), pulmonary (15\/8%), and hepatic (14.2%) events. Readmission rates are high (29% at 30 days, 49% at 180 days) and 64.2% have to permanently discontinue immune checkpoint inhibitor therapy. Importantly, multiple concurrent toxicities were seen in 21.6% (97\/450) of irAE admissions and these patients have a fivefold increased risk of inpatient death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13740","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T04:11:23Z","timestamp":1614744683000},"page":"514-522","source":"Crossref","is-referenced-by-count":48,"title":["Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018"],"prefix":"10.1093","volume":"26","author":[{"given":"Gabriel E.","family":"Molina","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Zubiri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine V.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sienna M.","family":"Durbin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Petrillo","sequence":"additional","affiliation":[{"name":"Division of Palliative Care, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonina R.","family":"Murciano-Goroff","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Mass General Center for Cancer Research, Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly F.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Mass General Center for Cancer Research, Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Faje","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rengarajan","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C.","family":"Guidon","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Okin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Medoff","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Nasrallah","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna J.","family":"Kohler","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara R.","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Karp Leaf","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Zlotoff","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn R.","family":"Farmer","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan J.","family":"Mooradian","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Mai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Chlo\u00e9","family":"Villani","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Center for Immunology and Inflammatory Diseases. Mass General Center for Cancer Research Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"2022020821442740400_onco13740-bib-0001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022020821442740400_onco13740-bib-0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for inhibitor checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2022020821442740400_onco13740-bib-0003","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2022020821442740400_onco13740-bib-0004","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022020821442740400_onco13740-bib-0005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2022020821442740400_onco13740-bib-0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102031","article-title":"Real world data in the era of immune checkpoint inhibitors (ICIs): Increasing evidence and future applications in lung cancer","volume":"87","author":"Pasello","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2022020821442740400_onco13740-bib-0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11519","article-title":"Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors","volume":"2","author":"Hsiehchen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2022020821442740400_onco13740-bib-0008","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/CJI.0000000000000186","article-title":"Efficacy and safety of pembrolizumab in patients enrolled in KEYNOTE-030 in the United States: An expanded access program","volume":"40","author":"Gangadhar","year":"2017","journal-title":"J Immunother"},{"key":"2022020821442740400_onco13740-bib-0009","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"2022020821442740400_onco13740-bib-0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022020821442740400_onco13740-bib-0011","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"2022020821442740400_onco13740-bib-0012","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022020821442740400_onco13740-bib-0013","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022020821442740400_onco13740-bib-0014","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022020821442740400_onco13740-bib-0015","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022020821442740400_onco13740-bib-0016","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2022020821442740400_onco13740-bib-0017","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"2022020821442740400_onco13740-bib-0018","first-page":"363","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"k4226","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"2022020821442740400_onco13740-bib-0019","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1200\/JOP.18.00703","article-title":"Immune-related adverse events requiring hospitalization: Spectrum of toxicity, treatment, and outcomes","volume":"15","author":"Balaji","year":"2019","journal-title":"J Oncol Pract"},{"key":"2022020821442740400_onco13740-bib-0020","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jgo.2020.01.006","article-title":"Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab","volume":"11","author":"Ksienski","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"2022020821442740400_onco13740-bib-0021","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/2326-6066.CIR-19-0986","article-title":"Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy","volume":"8","author":"Shah","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2022020821442740400_onco13740-bib-0022","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022020821442740400_onco13740-bib-0023","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022020821442740400_onco13740-bib-0024","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022020821442740400_onco13740-bib-0025","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor\u2013associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"2022020821442740400_onco13740-bib-0026","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2022020821442740400_onco13740-bib-0027","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022020821442740400_onco13740-bib-0028","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.19.01464","article-title":"Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade","volume":"38","author":"Warner","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022020821442740400_onco13740-bib-0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13740","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13740","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/514\/42375506\/oncolo_26_6_514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/514\/42375506\/oncolo_26_6_514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T16:51:53Z","timestamp":1644339113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/6\/514\/6520940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13740","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,3,31]]}}}